The DOI matches its Crossref record.
Upregulation of cyclin‐dependent kinase 7 and matrix metalloproteinase‐14 expression contribute to metastatic properties of gastric cancer
Abstract
The aim of this study was to evaluate the protein and mRNA expressions of matrix metalloproteinase‐14 (MMP14) and CDK7 in gastric cancer (GC) tissues. Upregulation of MMP14 mRNA level was observed in GC tissues when compared with the matched normal tissues (mean ± SD: 3.92 ± 1.15 vs. 1.35 ± 0.81, P < 0.001). This study indicated that mRNA levels of CDK7 were statistically overexpressed in GC when compared with matched normal tissues (4.12 ± 0.84 vs. 1.43 ± 0.71, P < 0.001). The protein levels of MMP14 were found to be increased in GC (60.41%; P < 0.001). The expression of CDK7 was higher in GC tissues than matched normal tissues (70.83; P < 0.001). We found that high MMP14 expression was related to advanced TNM stage (P = 0.004), tumor grade (P = 0.002), and lymph node metastasis (P = 0.015), but no association with other clinical variables (P > 0.05). In addition, high expression of CDK7 was significantly linked to advanced TNM stage (P = 0.001), pathological grade (P = 0.012), and presence of lymph node metastasis (P = 0.009), while no correlation between CDK7 expression and other clinical variables, such as age and gender, distance metastasis. The patients with high expression of MMP14 and CDK7 exhibited worse survival time than those with higher levels. Cox multivariate regression analysis clearly showed that high expression of MMP14 and CDK7 was independent prognostic factors for overall survival in patients with GC. Taken together, these results indicated the overexpression of above markers in the progression and the tumorigenesis of GC and overall patient survival. © 2016 IUBMB Life, 68(10):799–805, 2016
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis.
“It is well documented that MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis16,44,47–50.”
From Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis (2021) · cites this paper as [48]
The Discussion reports MMP14 overexpression in several cancers and links it to metastasis. The Introduction says MMP14 has been suggested to facilitate angiogenesis and cancer-cell dissemination, while the Discussion says it may promote angiogenesis. These passages support the general association but are more tentative than the claim that MT1-MMP promotes both outcomes as an established fact. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 37
- 10.1038/onc.2011.362 · DOI
- 10.3322/caac.21262 · DOI
- 10.3322/caac.21254 · DOI
- 10.1007/s00535-008-2177-6 · DOI
- Saglam S., 2011, A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma, J. Gastrointest. Oncol., 2, 19
- 10.1038/onc.2015.209 · DOI
- 10.3390/cancers6010416 · DOI
- 10.1074/jbc.M111.256644 · DOI · Paper page
- 10.1016/j.ccr.2014.07.020 · DOI
- 10.1074/jbc.M109.081687 · DOI
- 10.1016/j.cell.2014.10.024 · DOI
- 10.1016/j.gene.2015.03.003 · DOI
- 10.1111/his.12176 · DOI
- 10.1158/1535-7163.MCT-12-0001 · DOI
- 10.1097/PAI.0b013e318235a132 · DOI
- 10.1073/pnas.92.7.2730 · DOI
- 10.1007/s12013-014-9974-8 · DOI
- 10.1002/ijc.11313 · DOI
- 10.1007/s13277-014-2237-x · DOI · Paper page
- 10.1186/bcr1503 · DOI
- 10.1038/bjc.2013.676 · DOI
- 10.1016/j.arcmed.2015.03.006 · DOI
- 10.1038/onc.2012.1 · DOI
- 10.1152/ajpcell.00019.2009 · DOI
- 10.1016/j.yexcr.2006.01.008 · DOI
- 10.1038/modpathol.2014.32 · DOI
- 10.1007/s10620-012-2513-9 · DOI · Paper page
- 10.1074/jbc.M112.432005 · DOI
- 10.1016/j.yexmp.2016.05.001 · DOI
- Ebrahimi A., Diagnostic and prognostic potentials of KLF6 and HER3 expression alterations in cutaneous malignant melanoma, Tumour Biol.
- 10.1186/s13000-015-0371-4 · DOI
- Sadeghian Y., Profiles of tissue microRNAs; miR‐148b and miR‐25 serve as potential prognostic biomarkers for hepatocellular carcinoma, Tumour Biol.
- 10.1186/s13000-015-0338-5 · DOI
- Ebrahimi T., The value of U‐NGAL expression as a potential prognostic biomarker in patients with renal cancer after neoadjuvant chemotherapy with cisplatin, Tumour Biol.
- 10.1007/s13277-014-2854-4 · DOI
- 10.1007/s13277-014-2666-6 · DOI
- 10.1186/s12935-015-0237-6 · DOI
Cited by
Sorted by citations
Alabi, A., Xia, X.-D., Gu, H.-M., Wang, F., Deng, S.-J., Yang, N., Adijiang, A., Douglas, D. N., Kneteman, N. M., Xue, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22167-3 · Cited by 63
Metadata
- Authors
- Naseh, G., Mohammadifard, M., & Mohammadifard, M.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2016-08-25
- Volume
- 68
- Issue
- 10
- Pages
- 799-805
- ISSN
- 1521-6543
- 1521-6551
- Cited by
- 20
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
